Online inquiry

IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14844MR)

This product GTTS-WQ14844MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14844MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ141MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ15080MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ5565MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ12117MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ13198MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ5656MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ3505MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ2785MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-282
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW